Skip to Content

Novonesis AS Class B

NSIS B: XCSE (DNK)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
DKK 593.00WrkZgkxjhcp

Novozymes Augments Its Human Health Business With Synergia Acquisition; Shares Overvalued

After incorporating the acquisition of Synergia Life Sciences into our model, we maintain our DKK 375 fair value estimate for wide-moat Novozymes. At current levels, the shares look overvalued.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of NSIS B so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center